A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

Clinical trial NCT05175352 · COMPLETED

Trial details

NCT number: NCT05175352
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Eosinophilic Esophagitis

Start date: 2022-06-07
Primary completion: 2024-10-11
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.